Posoleucel
Cell therapyexperimental
Clinical trial activity
5 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
4
Phase 3
3
Phase 4
0
Earliest trial started Aug 15, 2020 (NCT04390113)
Timeline
Indications
Mechanism of action
- CytomegalovirusImmunity, passive
Cytomegalovirus immunity, passive
- Human herpesvirus 6Immunity, passive
Human herpesvirus 6 immunity, passive
- epstein-barr virusImmunity, passive
epstein-barr virus immunity, passive
- Human adenovirusImmunity, passive
Human adenovirus immunity, passive
- BK virusImmunity, passive
BK virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05179057 | Phase 3 | May 11, 2022 | AlloVir |
| NCT05305040 | Phase 2/Phase 3 (Phase 3) | Mar 21, 2022 | AlloVir |
| NCT04605484 | Phase 2 | Mar 22, 2021 | AlloVir |
| NCT04693637 | Phase 2 | Jan 15, 2021 | AlloVir |
| NCT04390113 | Phase 3 | Aug 15, 2020 | AlloVir |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| AlloVir | For profit | 5 | 5 | 2 | 2020 |
1 organizations
Page 1 / 1